Do you know how this 10% in 24 days metric compares to pre-clinical data for CagriSema and/or other GLP, GIP drugs?
I do not. I'm not sure any pre clinical comparison would make sense unless it was a head to head comparison done at the same time. (e.g. - Viking did a pre clinical comparison of VK2735 to Semaglutide and VK2735 showed superiority in that data).
"People are best convinced by reasons they discover themselves"
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.